Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Daxxin Psoriasis is a topical shampoo treatment developed and marketed by the Swedish pharmaceutical company Allderma. It is specifically formulated to alleviate symptoms associated with scalp psoriasis, seborrheic dermatitis, and persistent dandruff, such as itching, redness, and scaling. Classified as a CE-marked medical device, the product contains piroctone olamine as its primary active ingredient, which provides antifungal and antimicrobial properties. The formulation is designed to be gentle, excluding sulfates, phthalates, parabens, and cortisone, and includes guar gum for moisturizing. It is intended for daily use as a replacement for regular shampoo but is not a substitute for prescribed medical treatments like biologics or corticosteroids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Daxxin Psoriasis.